Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities
Philadelphia, Pennsylvania, U.S.A. August 18, 2020 Frontida BioPharm, Inc. today announced the completion of a facility expansion to their oral solid dose manufacturing operations with the commissioning of a Highly Potent Compound Contract Manufacturing Suite. This addition features 1000 sq. ft of readily available, hazard-certified production space.